LIVIVO - Search results -

Search results

Result 1 - 7 of total 7

Search options

Article ; Online: The self, neuroscience and psychosis study: Testing a neurophenomenological model of the onset of psychosis.

2023 Volume 18, Issue 2, Page(s) 153–164

Abstract: Aim: Basic self disturbance is a putative core vulnerability marker of schizophrenia spectrum disorders. The primary aims of the Self, Neuroscience and Psychosis (SNAP) study are to: (1) empirically test a previously described neurophenomenological self- ...

Abstract	Aim: Basic self disturbance is a putative core vulnerability marker of schizophrenia spectrum disorders. The primary aims of the Self, Neuroscience and Psychosis (SNAP) study are to: (1) empirically test a previously described neurophenomenological self-disturbance model of psychosis by examining the relationship between specific clinical, neurocognitive, and neurophysiological variables in UHR patients, and (2) develop a prediction model using these neurophenomenological disturbances for persistence or deterioration of UHR symptoms at 12-month follow-up. Methods: SNAP is a longitudinal observational study. Participants include 400 UHR individuals, 100 clinical controls with no attenuated psychotic symptoms, and 50 healthy controls. All participants complete baseline clinical and neurocognitive assessments and electroencephalography. The UHR sample are followed up for a total of 24 months, with clinical assessment completed every 6 months. Results: This paper presents the protocol of the SNAP study, including background rationale, aims and hypotheses, design, and assessment procedures. Conclusions: The SNAP study will test whether neurophenomenological disturbances associated with basic self-disturbance predict persistence or intensification of UHR symptomatology over a 2-year follow up period, and how specific these disturbances are to a clinical population with attenuated psychotic symptoms. This may ultimately inform clinical care and pathoaetiological models of psychosis.
MeSH term(s)	Humans ; Risk Factors ; Psychotic Disorders/psychology ; Schizophrenia/diagnosis ; Longitudinal Studies ; Attention ; Psychiatric Status Rating Scales
Language	English
Publishing date	2023-07-02
Publishing country	Australia
Document type	Observational Study ; Journal Article
ZDB-ID	2272425-4
ISSN	1751-7893 ; 1751-7885
ISSN (online)	1751-7893
ISSN	1751-7885
DOI	10.1111/eip.13448
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Preventive interventions for individuals at ultra high risk for psychosis: An updated and extended meta-analysis.

Mei, Cristina / van der Gaag, Mark / Nelson, Barnaby / Smit, Filip / Yuen, Hok Pan / Berger, Maximus / Krcmar, Marija / French, Paul / Amminger, G Paul / Bechdolf, Andreas / Cuijpers, Pim / Yung, Alison R / McGorry, Patrick D

Clinical psychology review

2021 Volume 86, Page(s) 102005

Abstract: Intervention at the earliest illness stage, in ultra or clinical high-risk individuals, or indicated prevention, currently represents the most promising strategy to ameliorate, delay or prevent psychosis. We review the current state of evidence and ... ...

Abstract	Intervention at the earliest illness stage, in ultra or clinical high-risk individuals, or indicated prevention, currently represents the most promising strategy to ameliorate, delay or prevent psychosis. We review the current state of evidence and conduct a broad-spectrum meta-analysis of various outcomes: transition to psychosis, attenuated positive and negative psychotic symptoms, mania, depression, anxiety, general psychopathology, symptom-related distress, functioning, quality of life, and treatment acceptability. 26 randomized controlled trials were included. Meta-analytically pooled interventions reduced transition rate (risk ratio [RR] = 0.57, 95%CI 0.41-0.81) and attenuated positive psychotic symptoms at 12-months (standardized mean difference = -0.15, 95%CI = -0.28--0.01). When stratified by intervention type (pharmacological, psychological), only the pooled effect of psychological interventions on transition rate was significant. Cognitive behavioral therapy (CBT) was associated with a reduction in incidence at 12-months (RR = 0.52, 95%CI = 0.33-0.82) and 18-48-months (RR = 0.60, 95%CI = 0.42-0.84), but not 6-months. Findings at 12-months and 18-48-months were robust in sensitivity and subgroup analyses. All other outcomes were non-significant. To date, effects of trialed treatments are specific to transition and, a lesser extent, attenuated positive symptoms, highlighting the future need to target other symptom domains and functional outcomes. Sound evidence supports CBT in reducing transition and the value of intervening at this illness stage. STUDY REGISTRATION: Research Registry ID: reviewregistry907.
MeSH term(s)	Cognitive Behavioral Therapy ; Humans ; Psychotic Disorders/prevention & control ; Quality of Life ; Risk
Language	English
Publishing date	2021-03-26
Publishing country	United States
Document type	Journal Article ; Meta-Analysis ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	604577-7
ISSN	1873-7811 ; 0272-7358
ISSN (online)	1873-7811
ISSN	0272-7358
DOI	10.1016/j.cpr.2021.102005
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1712: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A Sequential Adaptive Intervention Strategy Targeting Remission and Functional Recovery in Young People at Ultrahigh Risk of Psychosis: The Staged Treatment in Early Psychosis (STEP) Sequential Multiple Assignment Randomized Trial.

McGorry, Patrick D / Mei, Cristina / Amminger, G Paul / Yuen, Hok Pan / Kerr, Melissa / Spark, Jessica / Wallis, Nicky / Polari, Andrea / Baird, Shelley / Buccilli, Kate / Dempsey, Sarah-Jane A / Ferguson, Natalie / Formica, Melanie / Krcmar, Marija / Quinn, Amelia L / Mebrahtu, Yohannes / Ruslins, Arlan / Street, Rebekah / Wannan, Cassandra /

Dixon, Lisa / Carter, Cameron / Loewy, Rachel / Niendam, Tara A / Shumway, Martha / Nelson, Barnaby

JAMA psychiatry

2023 Volume 80, Issue 9, Page(s) 875–885

Abstract: Importance: Clinical trials have not established the optimal type, sequence, and duration of interventions for people at ultrahigh risk of psychosis.: Objective: To determine the effectiveness of a sequential and adaptive intervention strategy for ... ...

Abstract	Importance: Clinical trials have not established the optimal type, sequence, and duration of interventions for people at ultrahigh risk of psychosis. Objective: To determine the effectiveness of a sequential and adaptive intervention strategy for individuals at ultrahigh risk of psychosis. Design, setting, and participants: The Staged Treatment in Early Psychosis (STEP) sequential multiple assignment randomized trial took place within the clinical program at Orygen, Melbourne, Australia. Individuals aged 12 to 25 years who were seeking treatment and met criteria for ultrahigh risk of psychosis according to the Comprehensive Assessment of At-Risk Mental States were recruited between April 2016 and January 2019. Of 1343 individuals considered, 342 were recruited. Interventions: Step 1: 6 weeks of support and problem solving (SPS); step 2: 20 weeks of cognitive-behavioral case management (CBCM) vs SPS; and step 3: 26 weeks of CBCM with fluoxetine vs CBCM with placebo with an embedded fast-fail option of ω-3 fatty acids or low-dose antipsychotic medication. Individuals who did not remit progressed through these steps; those who remitted received SPS or monitoring for up to 12 months. Main outcomes and measures: Global Functioning: Social and Role scales (primary outcome), Brief Psychiatric Rating Scale, Scale for the Assessment of Negative Symptoms, Montgomery-Åsberg Depression Rating Scale, quality of life, transition to psychosis, and remission and relapse rates. Results: The sample comprised 342 participants (198 female; mean [SD] age, 17.7 [3.1] years). Remission rates, reflecting sustained symptomatic and functional improvement, were 8.5%, 10.3%, and 11.4% at steps 1, 2, and 3, respectively. A total of 27.2% met remission criteria at any step. Relapse rates among those who remitted did not significantly differ between SPS and monitoring (step 1: 65.1% vs 58.3%; step 2: 37.7% vs 47.5%). There was no significant difference in functioning, symptoms, and transition rates between SPS and CBCM and between CBCM with fluoxetine and CBCM with placebo. Twelve-month transition rates to psychosis were 13.5% (entire sample), 3.3% (those who ever remitted), and 17.4% (those with no remission). Conclusions and relevance: In this sequential multiple assignment randomized trial, transition rates to psychosis were moderate, and remission rates were lower than expected, partly reflecting the ambitious criteria set and challenges with real-world treatment fidelity and adherence. While all groups showed mild to moderate functional and symptomatic improvement, this was typically short of remission. While further adaptive trials that address these challenges are needed, findings confirm substantial and sustained morbidity and reveal relatively poor responsiveness to existing treatments. Trial registration: ClinicalTrials.gov Identifier: NCT02751632.
MeSH term(s)	Humans ; Female ; Adolescent ; Psychotic Disorders/diagnosis ; Fluoxetine/therapeutic use ; Quality of Life ; Antipsychotic Agents/therapeutic use ; Recurrence ; Treatment Outcome
Chemical Substances	Fluoxetine (01K63SUP8D) ; Antipsychotic Agents
Language	English
Publishing date	2023-06-28
Publishing country	United States
Document type	Randomized Controlled Trial ; Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
ZDB-ID	2701203-7
ISSN	2168-6238 ; 2168-622X
ISSN (online)	2168-6238
ISSN	2168-622X
DOI	10.1001/jamapsychiatry.2023.1947
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui I Zs.235: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Differential Expression of Anomalous Self-Experiences in Spontaneous Speech in Clinical High-Risk and Early-Course Psychosis Quantified by Natural Language Processing.

Biological psychiatry. Cognitive neuroscience and neuroimaging

2023 Volume 8, Issue 10, Page(s) 1005–1012

Abstract: Background: Basic self-disturbance, or anomalous self-experiences (ASEs), is a core feature of the schizophrenia spectrum. We propose a novel method of natural language processing to quantify ASEs in spoken language by direct comparison to an inventory ... ...

Abstract	Background: Basic self-disturbance, or anomalous self-experiences (ASEs), is a core feature of the schizophrenia spectrum. We propose a novel method of natural language processing to quantify ASEs in spoken language by direct comparison to an inventory of self-disturbance, the Inventory of Psychotic-Like Anomalous Self-Experiences (IPASE). We hypothesized that there would be increased similarity in open-ended speech to the IPASE items in individuals with early-course psychosis (PSY) compared with healthy individuals, with clinical high-risk (CHR) individuals intermediate in similarity. Methods: Open-ended interviews were obtained from 170 healthy control participants, 167 CHR participants, and 89 PSY participants. We calculated the semantic similarity between IPASE items and "I" sentences from transcribed speech samples using S-BERT (Sentence Bidirectional Encoder Representation from Text). Kolmogorov-Smirnov tests were used to compare distributions across groups. A nonnegative matrix factorization of cosine similarity was performed to rank IPASE items. Results: Spoken language of CHR individuals had the greatest semantic similarity to IPASE items when compared to both healthy control (s = 0.44, p < 10 Conclusions: We found that open-ended interviews elicited language with increased semantic similarity to the IPASE by participants in the CHR group compared with patients with psychosis. This demonstrates the utility of these methods for differentiating patients from healthy control participants. This complementary approach has the capacity to scale to large studies investigating phenomenological features of schizophrenia and potentially other clinical populations.
MeSH term(s)	Humans ; Speech ; Natural Language Processing ; Psychotic Disorders ; Schizophrenia
Language	English
Publishing date	2023-07-05
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	2879089-3
ISSN	2451-9030 ; 2451-9022
ISSN (online)	2451-9030
ISSN	2451-9022
DOI	10.1016/j.bpsc.2023.06.007
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: The self, neuroscience and psychosis study

Early Intervention in Psychiatry

Testing a neurophenomenological model of the onset of psychosis

2024 Volume 18, Issue 2, Page(s) 153–164

Title translation	Die "Self, Neuroscience and Psychosis"-Studie (SNPS): Erprobung eines neurophänomenologischen Modells für den Ausbruch einer Psychose (DeepL)
Abstract	Aim: Basic self disturbance is a putative core vulnerability marker of schizophrenia spectrum disorders. The primary aims of the Self, Neuroscience and Psychosis (SNAP) study are to: (1) empirically test a previously described neurophenomenological self-disturbance model of psychosis by examining the relationship between specific clinical, neurocognitive, and neurophysiological variables in UHR patients, and (2) develop a prediction model using these neurophenomenological disturbances for persistence or deterioration of UHR symptoms at 12-month follow-up. Methods: SNAP is a longitudinal observational study. Participants include 400 UHR individuals, 100 clinical controls with no attenuated psychotic symptoms, and 50 healthy controls. All participants complete baseline clinical and neurocognitive assessments and electroencephalography. The UHR sample are followed up for a total of 24 months, with clinical assessment completed every 6 months. Results: This paper presents the protocol of the SNAP study, including background rationale, aims and hypotheses, design, and assessment procedures. Conclusions: The SNAP study will test whether neurophenomenological disturbances associated with basic self-disturbance predict persistence or intensification of UHR symptomatology over a 2-year follow up period, and how specific these disturbances are to a clinical population with attenuated psychotic symptoms. This may ultimately inform clinical care and pathoaetiological models of psychosis.
Keywords	At Risk Populations ; Krankheitsbeginn ; Neurocognition ; Neurokognition ; Onset (Disorders) ; Prediction ; Psychose ; Psychosis ; Risikogruppen ; Symptome ; Symptoms ; Vorhersage
Language	English
Document type	Article
ZDB-ID	2272425-4
ISSN	1751-7893 ; 1751-7885
ISSN (online)	1751-7893
ISSN	1751-7885
DOI	10.1111/eip.13448
Database	PSYNDEX

Order via subito

Article: Preventive interventions for individuals at ultra high risk for psychosis

Mei, Cristina / van der Gaag, Mark / Nelson, Barnaby / Smit, Filip / Yuen, Hok Pan / Berger, Maximus / Krcmar, Marija / French, Paul / Amminger, G. Paul / Bechdolf, Andreas / Cuijpers, Pim / Yung, Alison R. / McGorry, Patrick D.

Clinical Psychology Review

An updated and extended meta-analysis

2021

Title translation	Präventive Interventionen für Personen mit extrem hohem Psychoserisiko: Eine aktualisierte und erweiterte Meta-Analyse
Abstract	Intervention at the earliest illness stage, in ultra or clinical high-risk individuals, or indicated prevention, currently represents the most promising strategy to ameliorate, delay or prevent psychosis. We review the current state of evidence and conduct a broad-spectrum meta-analysis of various outcomes: transition to psychosis, attenuated positive and negative psychotic symptoms, mania, depression, anxiety, general psychopathology, symptom-related distress, functioning, quality of life, and treatment acceptability. 26 randomized controlled trials were included. Meta-analytically pooled interventions reduced transition rate (risk ratio [RR] = 0.57, 95%CI 0.41-0.81) and attenuated positive psychotic symptoms at 12-months (standardized mean difference = -0.15, 95%CI = -0.28 - (-0.01). When stratified by intervention type (pharmacological, psychological), only the pooled effect of psychological interventions on transition rate was significant. Cognitive behavioral therapy (CBT) was associated with a reduction in incidence at 12-months (RR = 0.52, 95%CI = 0.33-0.82) and 18 & ndash;48-months (RR = 0.60, 95%CI = 0.42-0.84), but not 6-months. Findings at 12-months and 18 & ndash;48-months were robust in sensitivity and subgroup analyses. All other outcomes were non-significant. To date, effects of trialed treatments are specific to transition and, a lesser extent, attenuated positive symptoms, highlighting the future need to target other symptom domains and functional outcomes. Sound evidence supports CBT in reducing transition and the value of intervening at this illness stage. Study registration: Research Registry ID: reviewregistry907.
Keywords	Cognitive Behavior Therapy ; Familienintervention ; Family Intervention ; Fatty Acids ; Fettsäuren ; Kognitive Verhaltenstherapie ; Krankheitsbeginn ; Onset (Disorders) ; Predisposition ; Prevention ; Prädisposition ; Prävention ; Psychose ; Psychosis ; Risikofaktoren ; Risk Factors
Language	English
Document type	Article
ZDB-ID	604577-7
ISSN	1873-7811 ; 0272-7358
ISSN (online)	1873-7811
ISSN	0272-7358
DOI	10.1016/j.cpr.2021.102005
Database	PSYNDEX

In stock of ZB MED Cologne/Königswinter

Zs.A 1712: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis.

Wannan, Cassandra M J / Nelson, Barnaby / Addington, Jean / Allott, Kelly / Anticevic, Alan / Arango, Celso / Baker, Justin T / Bearden, Carrie E / Billah, Tashrif / Bouix, Sylvain / Broome, Matthew R / Buccilli, Kate / Cadenhead, Kristin S / Calkins, Monica E / Cannon, Tyrone D / Cecci, Guillermo / Chen, Eric Yu Hai / Cho, Kang Ik K / Choi, Jimmy /

Clark, Scott R / Coleman, Michael J / Conus, Philippe / Corcoran, Cheryl M / Cornblatt, Barbara A / Diaz-Caneja, Covadonga M / Dwyer, Dominic / Ebdrup, Bjørn H / Ellman, Lauren M / Fusar-Poli, Paolo / Galindo, Liliana / Gaspar, Pablo A / Gerber, Carla / Glenthøj, Louise Birkedal / Glynn, Robert / Harms, Michael P / Horton, Leslie E / Kahn, René S / Kambeitz, Joseph / Kambeitz-Ilankovic, Lana / Kane, John M / Kapur, Tina / Keshavan, Matcheri S / Kim, Sung-Wan / Koutsouleris, Nikolaos / Kubicki, Marek / Kwon, Jun Soo / Langbein, Kerstin / Lewandowski, Kathryn E / Light, Gregory A / Mamah, Daniel / Marcy, Patricia J / Mathalon, Daniel H / McGorry, Patrick D / Mittal, Vijay A / Nordentoft, Merete / Nunez, Angela / Pasternak, Ofer / Pearlson, Godfrey D / Perez, Jesus / Perkins, Diana O / Powers, Albert R / Roalf, David R / Sabb, Fred W / Schiffman, Jason / Shah, Jai L / Smesny, Stefan / Spark, Jessica / Stone, William S / Strauss, Gregory P / Tamayo, Zailyn / Torous, John / Upthegrove, Rachel / Vangel, Mark / Verma, Swapna / Wang, Jijun / Rossum, Inge Winter-van / Wolf, Daniel H / Wolff, Phillip / Wood, Stephen J / Yung, Alison R / Agurto, Carla / Alvarez-Jimenez, Mario / Amminger, Paul / Armando, Marco / Asgari-Targhi, Ameneh / Cahill, John / Carrión, Ricardo E / Castro, Eduardo / Cetin-Karayumak, Suheyla / Mallar Chakravarty, M / Cho, Youngsun T / Cotter, David / D'Alfonso, Simon / Ennis, Michaela / Fadnavis, Shreyas / Fonteneau, Clara / Gao, Caroline / Gupta, Tina / Gur, Raquel E / Gur, Ruben C / Hamilton, Holly K / Hoftman, Gil D / Jacobs, Grace R / Jarcho, Johanna / Ji, Jie Lisa / Kohler, Christian G / Lalousis, Paris Alexandros / Lavoie, Suzie / Lepage, Martin / Liebenthal, Einat / Mervis, Josh / Murty, Vishnu / Nicholas, Spero C / Ning, Lipeng / Penzel, Nora / Poldrack, Russell / Polosecki, Pablo / Pratt, Danielle N / Rabin, Rachel / Rahimi Eichi, Habiballah / Rathi, Yogesh / Reichenberg, Avraham / Reinen, Jenna / Rogers, Jack / Ruiz-Yu, Bernalyn / Scott, Isabelle / Seitz-Holland, Johanna / Srihari, Vinod H / Srivastava, Agrima / Thompson, Andrew / Turetsky, Bruce I / Walsh, Barbara C / Whitford, Thomas / Wigman, Johanna T W / Yao, Beier / Yuen, Hok Pan / Ahmed, Uzair / Byun, Andrew Jin Soo / Chung, Yoonho / Do, Kim / Hendricks, Larry / Huynh, Kevin / Jeffries, Clark / Lane, Erlend / Langholm, Carsten / Lin, Eric / Mantua, Valentina / Santorelli, Gennarina / Ruparel, Kosha / Zoupou, Eirini / Adasme, Tatiana / Addamo, Lauren / Adery, Laura / Ali, Munaza / Auther, Andrea / Aversa, Samantha / Baek, Seon-Hwa / Bates, Kelly / Bathery, Alyssa / Bayer, Johanna M M / Beedham, Rebecca / Bilgrami, Zarina / Birch, Sonia / Bonoldi, Ilaria / Borders, Owen / Borgatti, Renato / Brown, Lisa / Bruna, Alejandro / Carrington, Holly / Castillo-Passi, Rolando I / Chen, Justine / Cheng, Nicholas / Ching, Ann Ee / Clifford, Chloe / Colton, Beau-Luke / Contreras, Pamela / Corral, Sebastián / Damiani, Stefano / Done, Monica / Estradé, Andrés / Etuka, Brandon Asika / Formica, Melanie / Furlan, Rachel / Geljic, Mia / Germano, Carmela / Getachew, Ruth / Goncalves, Mathias / Haidar, Anastasia / Hartmann, Jessica / Jo, Anna / John, Omar / Kerins, Sarah / Kerr, Melissa / Kesselring, Irena / Kim, Honey / Kim, Nicholas / Kinney, Kyle / Krcmar, Marija / Kotler, Elana / Lafanechere, Melanie / Lee, Clarice / Llerena, Joshua / Markiewicz, Christopher / Matnejl, Priya / Maturana, Alejandro / Mavambu, Aissata / Mayol-Troncoso, Rocío / McDonnell, Amelia / McGowan, Alessia / McLaughlin, Danielle / McIlhenny, Rebecca / McQueen, Brittany / Mebrahtu, Yohannes / Mensi, Martina / Hui, Christy Lai Ming / Suen, Yi Nam / Wong, Stephanie Ming Yin / Morrell, Neal / Omar, Mariam / Partridge, Alice / Phassouliotis, Christina / Pichiecchio, Anna / Politi, Pierluigi / Porter, Christian / Provenzani, Umberto / Prunier, Nicholas / Raj, Jasmine / Ray, Susan / Rayner, Victoria / Reyes, Manuel / Reynolds, Kate / Rush, Sage / Salinas, Cesar / Shetty, Jashmina / Snowball, Callum / Tod, Sophie / Turra-Fariña, Gabriel / Valle, Daniela / Veale, Simone / Whitson, Sarah / Wickham, Alana / Youn, Sarah / Zamorano, Francisco / Zavaglia, Elissa / Zinberg, Jamie / Woods, Scott W / Shenton, Martha E

Schizophrenia bulletin

2024 Volume 50, Issue 3, Page(s) 496–512

Abstract: This article describes the rationale, aims, and methodology of the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ). This is the largest international collaboration to date that will develop algorithms to predict trajectories and outcomes of ... ...

Abstract	This article describes the rationale, aims, and methodology of the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ). This is the largest international collaboration to date that will develop algorithms to predict trajectories and outcomes of individuals at clinical high risk (CHR) for psychosis and to advance the development and use of novel pharmacological interventions for CHR individuals. We present a description of the participating research networks and the data processing analysis and coordination center, their processes for data harmonization across 43 sites from 13 participating countries (recruitment across North America, Australia, Europe, Asia, and South America), data flow and quality assessment processes, data analyses, and the transfer of data to the National Institute of Mental Health (NIMH) Data Archive (NDA) for use by the research community. In an expected sample of approximately 2000 CHR individuals and 640 matched healthy controls, AMP SCZ will collect clinical, environmental, and cognitive data along with multimodal biomarkers, including neuroimaging, electrophysiology, fluid biospecimens, speech and facial expression samples, novel measures derived from digital health technologies including smartphone-based daily surveys, and passive sensing as well as actigraphy. The study will investigate a range of clinical outcomes over a 2-year period, including transition to psychosis, remission or persistence of CHR status, attenuated positive symptoms, persistent negative symptoms, mood and anxiety symptoms, and psychosocial functioning. The global reach of AMP SCZ and its harmonized innovative methods promise to catalyze the development of new treatments to address critical unmet clinical and public health needs in CHR individuals.
MeSH term(s)	Humans ; Psychotic Disorders ; Schizophrenia ; Prospective Studies ; Adult ; Prodromal Symptoms ; Young Adult ; International Cooperation ; Adolescent ; Research Design/standards ; Male ; Female
Language	English
Publishing date	2024-03-07
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
ZDB-ID	439173-1
ISSN	1745-1701 ; 0586-7614
ISSN (online)	1745-1701
ISSN	0586-7614
DOI	10.1093/schbul/sbae011
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 1323: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Search results

Search options

Article ; Online: The self, neuroscience and psychosis study: Testing a neurophenomenological model of the onset of psychosis.

More links

Kategorien

Order via subito

Article ; Online: Preventive interventions for individuals at ultra high risk for psychosis: An updated and extended meta-analysis.

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Article ; Online: A Sequential Adaptive Intervention Strategy Targeting Remission and Functional Recovery in Young People at Ultrahigh Risk of Psychosis: The Staged Treatment in Early Psychosis (STEP) Sequential Multiple Assignment Randomized Trial.

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Article ; Online: Differential Expression of Anomalous Self-Experiences in Spontaneous Speech in Clinical High-Risk and Early-Course Psychosis Quantified by Natural Language Processing.

More links

Kategorien

Order via subito

Article: The self, neuroscience and psychosis study

More links

Kategorien

Order via subito

Article: Preventive interventions for individuals at ultra high risk for psychosis

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Article ; Online: Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis.

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito